Join BioVie Inc. for a virtual key opinion leader (KOL) event featuring Suzanne de la Monte, MD, MPH (Brown University Warren Alpert Medical School, Providence VA Medical Center) and Mark Stacy, MD (Medical University of South Carolina College of Medicine), who will join company management to discuss the unmet need and current treatment landscape for Parkinson’s disease.

The event will provide an update on BioVie’s Phase 2 trial evaluating bezisterim (NE3107) for the treatment of Parkinson’s disease. Bezisterim is a novel, orally-administered small molecule that has shown to reverse insulin resistance and selectively inhibit inflammation-driven ERK- and NF-κB-stimulated inflammatory mediators without inhibiting their homeostatic functions. Inflammation and the associated insulin resistance are required to create Parkinson’s symptoms. In addition, BioVie is currently enrolling patients recently diagnosed with Parkinson’s disease who have not yet begun treatment in order to assess the potential disease-modifying effects of bezisterim.

A live question and answer session will follow the formal presentations.